UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 137

Sortiert nach

13883 Maintenance of response through 136 weeks of long-term continuous risankizumab treatment: An analysis of patients from UltIMMa-1 and UltIMMa-2

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB14-AB14

2020

Link zum Volltext

Verfügbarkeit prüfen

15350 Consistent scalp psoriasis clearance with mirikizumab maintenance treatment at 104 weeks in patients who had less than PASI 90 response at week 16: A phase 2 study analysis

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB148-AB148

2020

Link zum Volltext

Verfügbarkeit prüfen

15984 Psoriasis patients treated with ixekizumab were maintained longer on monotherapy compared with other biologics in real-world clinical practice settings: Results from IBM MarketScan databases

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB52-AB52

2020

Link zum Volltext

Verfügbarkeit prüfen

16007 Ixekizumab demonstrated longer medication persistence than other biologics in the treatment of psoriasis patients: Results from IBM MarketScan databases

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB168-AB168

2020

Link zum Volltext

Verfügbarkeit prüfen

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis

Journal of the American Academy of Dermatology, 2014-12, Vol.71 (6), p.1176-1182

2014

Link zum Volltext

Verfügbarkeit prüfen

Absence of Borrelia burgdorferi in patients with localized scleroderma (morphea)

Journal of the American Academy of Dermatology, 1995-10, Vol.33 (4), p.682-684

1995

Link zum Volltext

Verfügbarkeit prüfen

Absence of human papillomavirus infection in cutaneous lichen planus

Journal of the American Academy of Dermatology, 1997-02, Vol.36 (2), p.267-268

1997

Link zum Volltext

Verfügbarkeit prüfen

ACROKERATOELASTOIDOSIS OF COSTA

International journal of dermatology, 1995-06, Vol.34 (6), p.431-433

1995

Link zum Volltext

Verfügbarkeit prüfen

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Journal of the American Academy of Dermatology, 2008, Vol.58 (1), p.106-115

2008

Link zum Volltext

Verfügbarkeit prüfen

Alefacept for psoriasis

Seminars in cutaneous medicine and surgery, 2010-03, Vol.29 (1), p.53-55

2010

Link zum Volltext

Verfügbarkeit prüfen

Analysis of the polymerase chain reaction in the detection of herpesvirus DNA from fixed and stained tissue sections

Archives of dermatology (1960), 1995-07, Vol.131 (7), p.805

1995

Link zum Volltext

Verfügbarkeit prüfen

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

The New England journal of medicine, 2012-03, Vol.366 (13), p.1190-1199

2012

Link zum Volltext

Verfügbarkeit prüfen

Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a

Seminars in cutaneous medicine and surgery, 2016-06, Vol.35 (4S), p.S74

Leonardi, Craig L

2016

Link zum Volltext

Verfügbarkeit prüfen

Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a

Seminars in cutaneous medicine and surgery, 2016-06, Vol.35 (4 Suppl 4), p.S74-S77

Leonardi, Craig L

2016

Link zum Volltext

Verfügbarkeit prüfen

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Journal of the American Academy of Dermatology, 2015-07, Vol.73 (1), p.37-49

2015

Link zum Volltext

Verfügbarkeit prüfen

Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials

JAMA : the journal of the American Medical Association, 2011-08, Vol.306 (8), p.864

2011

Link zum Volltext

Verfügbarkeit prüfen

Basal cell carcinoma of the scrotum

Journal of the American Academy of Dermatology, 1992-04, Vol.26 (4), p.574-578

1992

Link zum Volltext

Verfügbarkeit prüfen

Basal cell carcinoma of the scrotum : report of three cases and review of the literature

Journal of the American Academy of Dermatology, 1992-04, Vol.26 (4), p.574-578

1992

Link zum Volltext

Verfügbarkeit prüfen

A boxed warning for inadequate psoriasis treatment

Cutis (New York, N.Y.), 2016-09, Vol.98 (3), p.206-207

2016

Link zum Volltext

Verfügbarkeit prüfen

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

The New England journal of medicine, 2012-03, Vol.366 (13), p.1181-1189

2012

Link zum Volltext

Verfügbarkeit prüfen

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)

Journal of the American Academy of Dermatology, 2018-08, Vol.79 (2), p.302-314.e6

2018

Link zum Volltext

Verfügbarkeit prüfen

Clinical efficacy of efalizumab in patients with chronic plaque psoriasis : Results from three randomized placebo-controlled. Phase III trials: Part I

Journal of cutaneous medicine and surgery, 2005-12, Vol.9 (6), p.303-312

2005

Link zum Volltext

Verfügbarkeit prüfen

Clinical Efficacy of Efalizumab in Patients with Chronic Plaque Psoriasis: Results from Three Randomized Placebo-Controlled Phase III Trials: Part I

Journal of cutaneous medicine and surgery, 2005-12, Vol.9 (6), p.303-312

2005

Link zum Volltext

Verfügbarkeit prüfen

Clinical Goals and Barriers to Effective Psoriasis Care

Dermatology and therapy, 2019-03, Vol.9 (1), p.5-18

2019

Link zum Volltext

Verfügbarkeit prüfen

The clinical spectrum from classic varicella zoster to zoster sine herpete: the missing link

Archives of dermatology (1960), 1992-09, Vol.128 (9), p.1278

1992

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 137

Suche als RSS-Feed

Aktive Filter

KollektionTaylor & Francis:Master (3349 titles)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(124)
Mit Volltextzugriff
(100)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(86)
Dermatology
(85)
Life Sciences & Biomedicine
(83)
Humans
(82)
Psoriasis - Drug Therapy
(51)
Biological And Medical Sciences
(41)
Medical Sciences
(41)
Psoriasis
(41)
Female
(40)
Male
(40)
Middle Aged
(33)
Adult
(31)
Treatment Outcome
(27)
Severity Of Illness Index
(25)
Psoriasis. Parapsoriasis. Lichen
(24)
Antibodies, Monoclonal - Therapeutic Use
(20)
Aged
(18)
Antibodies, Monoclonal - Adverse Effects
(17)
Double-Blind Method
(17)
Antibodies, Monoclonal - Administration & Dosage
(16)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

13883 Maintenance of response through 136 weeks of long-term continuous risankizumab treatment: An analysis of patients from UltIMMa-1 and UltIMMa-2

15350 Consistent scalp psoriasis clearance with mirikizumab maintenance treatment at 104 weeks in patients who had less than PASI 90 response at week 16: A phase 2 study analysis

15984 Psoriasis patients treated with ixekizumab were maintained longer on monotherapy compared with other biologics in real-world clinical practice settings: Results from IBM MarketScan databases

16007 Ixekizumab demonstrated longer medication persistence than other biologics in the treatment of psoriasis patients: Results from IBM MarketScan databases

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis

Absence of Borrelia burgdorferi in patients with localized scleroderma (morphea)

Absence of human papillomavirus infection in cutaneous lichen planus

ACROKERATOELASTOIDOSIS OF COSTA

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Alefacept for psoriasis

Analysis of the polymerase chain reaction in the detection of herpesvirus DNA from fixed and stained tissue sections

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a

Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials

Basal cell carcinoma of the scrotum

Basal cell carcinoma of the scrotum : report of three cases and review of the literature

A boxed warning for inadequate psoriasis treatment

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)

Clinical efficacy of efalizumab in patients with chronic plaque psoriasis : Results from three randomized placebo-controlled. Phase III trials: Part I

Clinical Efficacy of Efalizumab in Patients with Chronic Plaque Psoriasis: Results from Three Randomized Placebo-Controlled Phase III Trials: Part I

Clinical Goals and Barriers to Effective Psoriasis Care

The clinical spectrum from classic varicella zoster to zoster sine herpete: the missing link

Aktive Filter

Suchergebnisse filtern